US food and drug administration approval of liposomal amphotericin B for the treatment of visceral leishmaniasis: A model for orphan drug development
Clinical Trials Review
- 30 Downloads
- 4 Citations
Keywords
Visceral Leishmaniasis Leishmaniasis Cutaneous Leishmaniasis Liposomal Amphotericin AmBisome
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
- 1.MeyerhoffA: U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999, 28:42–48.PubMedGoogle Scholar
- 2.Berman JD: U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis [editorial]. Clin Infect Dis 1999, 28:49–51.PubMedGoogle Scholar
- 3.Catania S, Aiassa C, Tzahtzoglou S, et al.: Visceral leishmaniasis treated with liposomal amphotericin B. Pediatr Infect Dis J 1999, 18:73–74.PubMedCrossRefGoogle Scholar
- 4.Berman JD, Badaro R, Thakur CP, et al.: Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull WHO 1998, 76:25–32.PubMedGoogle Scholar
- 5.Sundar S, Goyal AK, More DK, et al.: Treatment of antimonyunresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol 1998, 92:755–764.PubMedCrossRefGoogle Scholar
- 6.Wortmann GW, Fraser SL, Aronson NE, et al.: Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis 1998, 26:1006–1007.PubMedCrossRefGoogle Scholar
Copyright information
© Current Science Inc 1999